Treating Acute Leukemias in the Asia Pacific Region

Emerging and Practical Concepts and Controversies in Leukemias

Overview

In recent years, progress in the understanding of acute leukemias has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Leukemia Academy to help physicians who treat acute leukemias bridge the gap between innovation and implementation for patient care.

Date and Location

May 15–16, 2021, Virtual Meeting

Meeting Content

View the slides and watch the video of Day 1
ALL Plenary Session

View the slides and watch the video of Day 2
Adult Leukemia Session

View slides and watch the video of Day 2
Pediatric ALL Session

Faculty

Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center, USA

Patrick Brown

Patrick A. Brown, MD

Johns Hopkins University School of Medicine, USA

Naval Daver, MD

MD Anderson Cancer Center (MDACC), Houston, TX

Eunice Wang, MD

Roswell Park Comprehensive Cancer Center, USA

José Maria Ribera

José Maria Ribera, MD, PhD

Catalan Institute of Oncology, University Hospital Germans Trias i Pujol, Spain

Aaron Logan

Aaron Logan, MD, PhD

UCSF, Helen Diller Family Comprehensive Cancer Care, USA

Lia Gore

Lia Gore, MD

University of Colorado, Anschutz Medical Campus, USA

Agenda

This 2-day interactive virtual meeting with global experts will focus on the management of acute leukemias in adult, young adult, and pediatric patients in various countries within the Asia Pacific region.

Day 1: Follow presentations, interact in panel discussions, and debate about novel approved therapies, evolving treatment paradigms, and other hot topics, including patient management during the COVID-19 pandemic.

Day 2: Join the pediatric or adult breakout session to learn about treatment strategies for newly diagnosed and relapsed ALL patients and attend the patient case-based panel discussion about toxicity management.

Day 1 – PLENARY SESSIONS Saturday, May 15, 2021
Chair: Elias Jabbour, MD

9.00 – 13.00 JST/UTC +9 (Japan Standard Time)
8.00 – 12.00 HKT/UTC +8 (Hong Kong Time)

Japan Time (UTC +9) Topic Presenter
9.00 – 9.10 Welcome and meeting overview; introduction to the voting system Elias Jabbour
9.10 – 9.50 Recent developments in acute leukemias Elias Jabbour
9.50 – 10.15 Review of prognostic value of MRD in acute leukemias Aaron Logan
10.15 – 10.30 Genetic variants in ALL – Ph+ and Ph-like José Maria Ribera
10.30 – 10.45 AYA ALL patients – what is the current treatment approach for this diverse patient population? Lia Gore
10.45 – 10.55 Break  
10.55 – 11.10 Bispecifics as post-reinduction therapy improve survival in high-risk first-relapse pediatric and AYA B-ALL Patrick Brown
11.10 – 11.35 Therapeutic approaches in high-risk and older AML patients Naval Daver
11.35 – 12.20 Leukemia board discussion
• Regional challenges in times of COVID-19 – Shaun Fleming (20 min)
• Case discussion – Bhavna Padhye (15 min)
• Discussion (10 min)

Moderator: Elias Jabbour

All faculty

12.20 – 12.50 Debate on sequencing CD19-targeted approaches
• Monoclonal antibodies and bispecifics first (10 min)
• CAR T first (10 min)
• Discussion and voting (10 min)

Moderator: Aaron Logan

Elias Jabbour

José Maria Ribera
All faculty

12.50 – 13.00 Session close Elias Jabbour

Day 2 – BREAKOUT: ADULT LEUKEMIA PATIENTS Sunday, May 16, 2021

Chair: Elias Jabbour, MD

11.00 – 14.30 JST/UTC +9 (Japan Standard Time)
10.00 – 13.30 HKT/UTC +8 (Hong Kong Time)

Japan Time (UTC +9) Topic Presenter
11.00 – 11.15 Session open
• Educational ARS questions for the audience
Elias Jabbour
11.15 – 11.35 Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens
• Presentation (15 min)
• Q&A (5 min)
Aaron Logan
11.35 – 11.55 Current treatment options for relapsed ALL in adult and elderly patients (including COVID-19 and vaccination strategy)
• Presentation (15 min)
• Q&A (5 min)
José Maria Ribera, MD
11.55 – 12.30 Case-based panel discussion: Management of long- and short-term toxicities and treatment selection in adult and elderly patients
Panelists: Elias Jabbour, Aaron Logan, Local Experts
Shaun Fleming
12.30 – 12.45 Break  
12.45 – 13.05 Personalized induction and maintenance approaches for AML
• Presentation (15 min)
• Q&A (5 min)
Naval Daver
13.05 – 13.25 Optimizing management of relapsed/refractory AML
• Presentation (15 min)
• Q&A (5 min)
Eunice Wang
13.25 – 14.15 Case-based panel discussion or questions to the panel on regional challenges in AML care Case 1: Chyn Chua
Case 2: Sun Loo
14.15 – 14.30 Session close
• Educational ARS questions for the audience
Elias Jabbour

Day 2 – BREAKOUT: PEDIATRIC ALL PATIENTS Sunday, May 16, 2021

Chair: Patrick Brown

11.00 – 13.30 JST/UTC +9 (Japan Standard Time)
10.00 – 12.30 HKT/UTC +8 (Hong Kong Time)

Japan Time (UTC +9) Topic Presenter
11.00 – 11.15 Session open
• Educational ARS questions for the audience
Patrick Brown
11.15 – 11.35 First-line treatment of pediatric ALL
• Presentation (15 min)
• Q&A (5 min)
Bhavna Padhye
11.35 – 11.55 Current treatment options for relapsed ALL in children, including HSCT; COVID-19 considerations and vaccinations
• Presentation (15 min)
• Q&A (5 min)
Michael Osborn
11.55 – 12.15 Bispecifics for pediatric ALL, focus on frontline therapy
• Presentation (15 min)
• Q&A (5 min)
Patrick Brown
12.15 – 12.45 Case-based panel discussion: Management of long-and short-term toxicities and treatment selection in pediatric patients
Panelists: All faculty
Case 1: Bhavna Padhye (10 min)
Case 2: Michael Osborn (10 min)
Discussion (10 min)
12.45 – 13.30 Interactive Q&A and session close
• Educational ARS questions for the audience
Patrick Brown